NeuCyte

NeuCyte, founded in 2015 and headquartered in the United States, is pioneering advancements in the biotechnology sector with a focus on central nervous system (CNS) drug discovery. Their slogan, "Decoding CNS Drug Discovery with SynFire® iP," encapsulates their mission of refining preclinical testing methodologies. By employing a cutting-edge human neural platform, NeuCyte offers a novel approach that better predicts drug efficacy compared to traditional animal models, thus reducing the costly attrition rates in novel drug trials.

Received in the form of a $6.70M Series A investment on 08 May 2018 from investors Cowin Venture and Leaguer Venture Capital, the company has demonstrated solid growth potential. Its team, comprising top-tier stem cell biologists and neuroscientists, provides a significant competitive advantage. This positions NeuCyte as a noteworthy contender addressing unmet needs in the pharmaceutical and healthcare industries.